IP 1009

Drug Profile

IP 1009

Latest Information Update: 08 Jun 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Indevus Pharmaceuticals
  • Class Hypnosedatives; Sleep disorder therapies; Small molecules; Tryptamines
  • Mechanism of Action Melatonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Insomnia

Most Recent Events

  • 08 Jun 2001 Discontinued-Preclinical for Insomnia in USA (PO)
  • 15 Jan 1999 Suspended-Preclinical for Insomnia in USA (PO)
  • 20 Feb 1997 Preclinical development for Insomnia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top